A Phase 3 interventional study of Upadacitinib and Dupilumab in Atopic Dermatitis, sponsored by AbbVie. Completed at 159 sites in 23 countries. Open to participants aged 18 Years to 76 Years. Per ClinicalTrials.gov, last updated 2024-03-15.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing upadacitinib in Dermatitis, Atopic — 2 open to participants now, 6 under way, 4 of them phase 3. upadacitinib · Dermatitis, Atopic.
Among the 17 studies testing upadacitinib in Dermatitis, Atopic, this one is the 6th largest by enrollment, is one of 2 that started in 2019, is one of 12 in phase 3, and was the 7th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →2 of the 17 studies testing upadacitinib in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
RenJi Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 76 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 673 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 272 across the 17 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 17 have an industry lead sponsor. The 3 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
34 studies in Dermatitis, Atopic by AbbVie: 3 open now, 12 under way, 4 of them phase 3. Of 19 finished, 8 (42%) have results posted.
Among the 34 studies in Dermatitis, Atopic by AbbVie, this one is the 6th largest by enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2019, is one of 12 in phase 3, and was the 8th registered.
AbbVie’s Dermatitis, Atopic studies by the year they started, since 2016.
3 of the studies testing upadacitinib in Dermatitis, Atopic that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06389136Phase 3AbbVieA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | 2026-11 |
| NCT06701331Phase 3AbbVieSafety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis | 2027-01 |
| NCT07678645RenJi HospitalThe Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching | 2027-11-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies testing upadacitinib in Dermatitis, Atopic, from their registry updates:
Among AbbVie’s 34 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
This study will evaluate upadacitinib compared to dupilumab (Dupixent®) in adults with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
The study is comprised of a 35-day screening period, a 24-week double-blinded treatment period, and a follow-up visit 12 weeks after the last dose. Participants who complete Week 24 have the option to enroll into an open-label study (Study M19-850; NCT04195698) of upadacitinib 30 mg once daily and receive treatment with upadacitinib for an additional 52 weeks.
Participants who meet eligibility criteria will be randomized in a 1:1 ratio to receive either upadacitinib or dupilumab. Randomization will be stratified by Baseline disease severity (Validated Investigator Global Assessment scale for Atopic Dermatitis [vIGA-AD] score of moderate [3] versus severe [4]) and age (\<40, ≥ 40 to \< 65, ≥ 65 years).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive 30 mg upadacitinib orally once a day (QD) up to Week 24 and placebo to dupilumab by subcutaneous injection every other week from Baseline to Week 22.
Biological: Upadacitinib · Drug: Placebo to dupilumab
Participants will receive a loading dose of 600 mg dupilumab by subcutaneous (SC) injection on Day 1 followed by 300 mg dupilumab SC every other week (EOW) until Week 22 and placebo to upadacitinib orally QD up to Week 24.
Biological: Dupilumab · Drug: Placebo to upadacitinib
Extended release tablet
Also known as: ABT-494, RINVOQ®
Dupilumab is administered as a subcutaneous (SC) injection
Also known as: Dupixent®
Placebo administered as a subcutaneous injection
Tablet
Percentage of Participants Achieving a 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
Time frame: Baseline and Week 16
Percent Change From Baseline in Worst Pruritus Numerical Rating Scale (NRS) Score at Week 16
The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The percent change from Baseline was calculated from a rolling weekly average; a negative change from Baseline indicates improvement.
Time frame: Baseline (Week 0) to Week 16
Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
Time frame: Baseline and Week 16
Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
Time frame: Baseline and Week 16
Percent Change From Baseline in Worst Pruritus Numerical Rating Scale (NRS) Score at Week 4
The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The percent change from Baseline was calculated from a rolling weekly average; a negative change from Baseline indicates improvement.
Time frame: Baseline (Week 0) to Week 4
Percentage of Participants Achieving a 75% Reduction From Baseline in EASI Score at Week 2
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
Time frame: Baseline and Week 2
Percent Change From Baseline in Worst Pruritus Numerical Rating Scale (NRS) Score at Week 1
The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The percent change from Baseline was calculated from a rolling weekly average; a negative change from Baseline indicates improvement.
Time frame: Baseline (Week 0) to Week 1
Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 16
The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
Time frame: Baseline and Week 16
Participants were randomized at 128 sites located in 22 countries (Australia, Canada, Croatia, Czechia, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Malaysia, Netherlands, New Zealand, Norway, Poland, Singapore, Spain, Taiwan, Ukraine, United Kingdom, and the United States).
| Milestone | Dupilumab 300 mg EOW | Upadacitinib 30 mg QD |
|---|---|---|
| Started | 331 | 342 |
| Completed | 308 | 312 |
| Not completed | 23 | 30 |
| Withdrew: Adverse event | 3 | 7 |
| Withdrew: Withdrawal by subject | 8 | 11 |
| Withdrew: Lost to follow-up | 7 | 5 |
| Withdrew: Covid-19 logistical restrictions | 1 | 1 |
| Withdrew: Other | 4 | 6 |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
| percentage of participants | Dupilumab 300 mg EOW | Upadacitinib 30 mg QD |
|---|---|---|
| Percentage of Participants Achieving a 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 16 | 62.6 (57.4 to 67.8) | 72.4 (67.6 to 77.2) |
The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The percent change from Baseline was calculated from a rolling weekly average; a negative change from Baseline indicates improvement.
| percent change | Dupilumab 300 mg EOW | Upadacitinib 30 mg QD |
|---|---|---|
| Percent Change From Baseline in Worst Pruritus Numerical Rating Scale (NRS) Score at Week 16 | -49.58 ± 1.986 | -67.78 ± 1.906 |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
| percentage of participants | Dupilumab 300 mg EOW | Upadacitinib 30 mg QD |
|---|---|---|
| Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 16 | 7.9 (5.0 to 10.8) | 28.4 (23.6 to 33.2) |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
| percentage of participants | Dupilumab 300 mg EOW | Upadacitinib 30 mg QD |
|---|---|---|
| Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 16 | 40.3 (35.0 to 45.6) | 61.6 (56.4 to 66.8) |
The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The percent change from Baseline was calculated from a rolling weekly average; a negative change from Baseline indicates improvement.
| percent change | Dupilumab 300 mg EOW | Upadacitinib 30 mg QD |
|---|---|---|
| Percent Change From Baseline in Worst Pruritus Numerical Rating Scale (NRS) Score at Week 4 | -32.39 ± 2.288 | -60.41 ± 2.204 |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
| percentage of participants | Dupilumab 300 mg EOW | Upadacitinib 30 mg QD |
|---|---|---|
| Percentage of Participants Achieving a 75% Reduction From Baseline in EASI Score at Week 2 | 18.2 (14.0 to 22.4) | 44.3 (39.1 to 49.6) |
The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The percent change from Baseline was calculated from a rolling weekly average; a negative change from Baseline indicates improvement.
| percent change | Dupilumab 300 mg EOW | Upadacitinib 30 mg QD |
|---|---|---|
| Percent Change From Baseline in Worst Pruritus Numerical Rating Scale (NRS) Score at Week 1 | -8.94 ± 1.831 | -31.96 ± 1.772 |
The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
| percentage of participants | Dupilumab 300 mg EOW | Upadacitinib 30 mg QD |
|---|---|---|
| Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 16 | 36.4 (31.1 to 41.6) | 56.1 (50.8 to 61.5) |
Collected over All-cause mortality was recorded from Day 1 up to 12 weeks after last injection (34 weeks). Treatment-emergent adverse events are from first dose of upadacitinib/dupilumab through 30 days following the last dose of upadacitinib or 84 days following the last dose of dupilumab (up to 34 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dupilumab 300 mg EOW | 0/331 (0%) | 7/331 (2.1%) | 134/331 (40.5%) |
| Upadacitinib 30 mg QD | 1/342 (0.3%) | 14/342 (4.1%) | 167/342 (48.8%) |
| Event | Dupilumab 300 mg EOW | Upadacitinib 30 mg QD |
|---|---|---|
| INCARCERATED UMBILICAL HERNIAGastrointestinal disorders | 1/331 | 0/342 |
| TYPE I HYPERSENSITIVITYImmune system disorders | 1/331 | 0/342 |
| CELLULITISInfections and infestations | 1/331 | 0/342 |
| ERYSIPELASInfections and infestations | 1/331 | 0/342 |
| PELVIC FRACTUREInjury, poisoning and procedural complications | 1/331 | 0/342 |
| BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations | 1/331 | 0/342 |
| BURSITISMusculoskeletal and connective tissue disorders | 1/331 | 0/342 |
| ASTHMARespiratory, thoracic and mediastinal disorders | 1/331 | 0/342 |
| LYMPHOPENIABlood and lymphatic system disorders | 0/331 | 1/342 |
| NEUTROPENIABlood and lymphatic system disorders | 0/331 | 1/342 |
| Event | Dupilumab 300 mg EOW | Upadacitinib 30 mg QD |
|---|---|---|
| ACNESkin and subcutaneous tissue disorders | 11/331 | 64/342 |
| CONJUNCTIVITISInfections and infestations | 35/331 | 5/342 |
| DERMATITIS ATOPICSkin and subcutaneous tissue disorders | 32/331 | 36/342 |
| NASOPHARYNGITISInfections and infestations | 27/331 | 23/342 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 17/331 | 26/342 |
| BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations | 10/331 | 26/342 |
| HEADACHENervous system disorders | 24/331 | 17/342 |
| FOLLICULITISInfections and infestations | 4/331 | 22/342 |
| URINARY TRACT INFECTIONInfections and infestations | 15/331 | 18/342 |
| ORAL HERPESInfections and infestations | 9/331 | 17/342 |
The intent-to-treat (ITT) population includes all randomized participants according to the treatment groups that they were randomized to.
| Age, Continuous(years) | Dupilumab 300 mg EOW | Upadacitinib 30 mg QD | Total |
|---|---|---|---|
| Mean | 36.3 ± 13.81 | 36.2 ± 14.42 | 36.3 ± 14.11 |
| Age, Customized(Participants) | Dupilumab 300 mg EOW | Upadacitinib 30 mg QD | Total |
|---|---|---|---|
| < 40 years | 223 | 228 | 451 |
| ≥ 40 to < 65 years | 94 | 98 | 192 |
| ≥ 65 years | 14 | 16 | 30 |
| Sex: Female, Male(Participants) | Dupilumab 300 mg EOW | Upadacitinib 30 mg QD | Total |
|---|---|---|---|
| Female | 139 | 159 | 298 |
| Male | 192 | 183 | 375 |
| Ethnicity (NIH/OMB)(Participants) | Dupilumab 300 mg EOW | Upadacitinib 30 mg QD | Total |
|---|---|---|---|
| Hispanic or Latino | 31 | 25 | 56 |
| Not Hispanic or Latino | 300 | 317 | 617 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Dupilumab 300 mg EOW | Upadacitinib 30 mg QD | Total |
|---|---|---|---|
| White | 231 | 229 | 460 |
| Black or African American | 15 | 25 | 40 |
| Asian | 78 | 77 | 155 |
| American Indian/Alaska Native | 1 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 1 | 3 | 4 |
| Multiple | 5 | 6 | 11 |
| Disease Severity(Participants) | Dupilumab 300 mg EOW | Upadacitinib 30 mg QD | Total |
|---|---|---|---|
| 3 (Moderate) | 159 | 169 | 328 |
| 4 (Severe) | 172 | 173 | 345 |
| Eczema Area and Severity Index (EASI) Score(score on a scale) | Dupilumab 300 mg EOW | Upadacitinib 30 mg QD | Total |
|---|---|---|---|
| Mean | 29.21 ± 11.551 | 30.96 ± 12.550 | 30.10 ± 12.092 |
| Duration Since AD Diagnosis(years) | Dupilumab 300 mg EOW | Upadacitinib 30 mg QD | Total |
|---|---|---|---|
| Mean | 25.474 ± 14.8251 | 23.608 ± 14.7697 | 24.526 ± 14.8154 |
Showing the first 100 of 159 sites across 23 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing, please refer to the link below.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · vivli.org
Ran from Feb 2019 to primary completion in Aug 2020, 18 months.
Results were first posted in Feb 2022, 1 year 5 months after primary completion. A results delay was requested in Jul 2021.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 18 months is close to that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Upadacitinib